News
Why Viking Therapeutics stock reaction to obesity pill data is wildly ‘overdone’
Viking Therapeutics Inc (NASDAQ: VKTX) reported new clinical data for its oral obesity drug – sending shares sharply lower as investors balked at tolerability concerns and dropout rates. The Phase 2 trial showed promising weight loss results,
The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...
Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...
MarketBeat on MSN4h
Is Viking's Growth Still Worth the Premium?
Viking (NYSE: VIK) stock is down approximately 3% after the cruise line’s second-quarter earnings report. The company ...
Viking Holdings Ltd (NYSE: VIK) shares slipped despite strong Q2 results and positive analyst outlook. Pricing power and ...
Viking Therapeutics Inc.’s worst stock drop in nine years has handed traders betting against the company a gain big enough to ...
The modern Viking diet emphasizes whole foods over ultraprocessed options, with experts recommending home cooking and ...
Fair gates open at 10 a.m. and close at 10 p.m. weekdays and 11 p.m. weekends Friday, Aug. 22, through Monday, Sept. 1, Oregon State Fairgrounds, 2330 17th St. N.E. Salem; admission $3-$12, ages 5 and ...
Viking? Royal Caribbean? Celebrity? What is Dan's favorite cruise line originally appeared on TravelHost. Everyone asks ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback